Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Restoring Radioiodine Avidity in Radioiodine-refractory Differentiated Thyroid Cancer With Genotype-guided MAPK Inhibition and Dosimetry-guided Radioiodine.

Clinical nuclear medicine - 1 May 2026

Demirkol Mehmet Onur, Kaya Gursan, Seymen Hulya, Alagol Faruk, Selcukbiricik Fatih

Abstract excerpt

BACKGROUND: To evaluate the real-world effectiveness and safety of short-course MAPK pathway inhibition, integrated with individualized dosimetry, as a redifferentiation strategy in patients with radioiodine-refractory differentiated thyroid cancer (RAIR-DTC). PATIENTS AND METHODS: This retrospective single-center cohort included 11 patients with RAIR-DTC who underwent genotype-directed redifferentiation therapy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Cell Differentiation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRAF gene

Share to Genotype

Share to Iodine Radioisotopes

Share to Mitogen-Activated Protein Kinases

Share to Protein Kinase Inhibitors

Share to Thyroid Neoplasms

Source

Identifiers

PMID: 41686811
DOI: 10.1097/RLU.0000000000006362

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Restoring Radioiodine Avidity in Radioiodine-refractory Differentiated Thyroid Cancer With Genotype-guided MAPK Inhibition and Dosimetry-guided Radioiodine.PMID 41686811Read ↗

Targeted therapy in thyroid cancer: molecular alterations and clinical management.Semantic proximity Read ↗

Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine.Semantic proximity Read ↗

Short-Term BRAF Inhibition with Dabrafenib induced redifferentiation in a subset of patients with BRAF V600E-Mutant papillary thyroid carcinoma.Semantic proximity Read ↗

Enhancing Radioiodine Incorporation in BRAF-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial.Semantic proximity Read ↗

Molecular Profile of Advanced Radioiodine-refractory Thyroid Cancer and Response to Lenvatinib Treatment.Semantic proximity Read ↗

Non-Iodine-Avid Disease Is Highly Prevalent in Distant Metastatic Differentiated Thyroid Cancer With Papillary Histology.Semantic proximity Read ↗

Clinical relevance of gene mutations and rearrangements in advanced differentiated thyroid cancer.Semantic proximity Read ↗

Efficacy of Radioiodine in Non-Distant Metastatic Papillary Thyroid Cancer with TERT-p Mutation at Initial DiagnosisSemantic proximity Read ↗

Does Molecular Genotype Provide Useful Information in the Management of Radioiodine Refractory Thyroid Cancers? Results of a Retrospective Study.Semantic proximity Read ↗

Pathological processes and therapeutic advances in radioiodide refractory thyroid cancer.Semantic proximity Read ↗

Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic Thyroid Cancer.Semantic proximity Read ↗

Lesional dosimetry in 131I refractory metastatic differentiated thyroid cancer with BRAFp.V600E or RAS mutation treated with trametinib +/- dabrafenib followed by radioactive iodine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.